RESPOND Study

Resuscitation in Paediatric Septic Shock using Hydrocortisone, Vitamin C, and Thiamine - A Randomised Controlled Multicentre Trial (RESPOND study)

One potential strategy to hasten shock resolution consists of using intravenous steroids. Recently, the combination of intravenous Hydrocortisone with Thiamine and Vitamin C, postulated to support metabolic dysfunction and reduce sepsis-related endothelial dysfunction, has been proposed as a safe and economic strategy with dramatic improvement reported in single center adult observational studies. 

In view of the controversy around currently recommended paediatric sepsis resuscitation treatment, and the potential promise of early metabolic resuscitation, we believe that a randomised control trial to investigate this is justified. The interventions are based on easily available drugs with well described safety profile. Additionally, they are cheap and widely used in paediatrics.

Sepsis is a leading cause of death and disability in children globally accounting for over >1million childhood deaths per year. In Australia and New Zealand, over 50 children die each year because of sepsis and total hospitalization related costs due to sepsis amount to >$100M annually. Up to a third of sepsis survivors suffer from long term disabilities related to amputations and neurological impairment. Several therapeutic approaches have failed to show a mortality benefit and sepsis outcome improvements have been moderate at best in children over the past decade.

Despite large campaigns and quality improvement initiatives implementing sepsis treatment bundles consisting of intravenous antibiotics, aggressive fluid boluses, followed by inotropes and consideration for intravenous steroids, the evidence for interventions other than antibiotics is limited. Both the treatment recommendations and the selection of therapeutic endpoints are largely based on expert consensus and limited low grade evidence resulting from earlier observational studies. This indicates an urgent need for novel sepsis resuscitation studies in children. 

Paediatric sepsis is a rapidly progressive disease with onset of sepsis-related Multi Organ Dysfunction Syndrome and the majority of deaths occurring within 48 hours of presentation, hence sepsis interventions need to be applied early during disease to modify outcome. In contrast to previous septic shock studies targeting children in PICU at advanced stages of disease, this study therefore is aiming to intervene early after presentation to Emergency Departments and Intensive Care Units using prospective consent and consent to continue. The study design is based on the experience from a pilot study conducted at our site which has confirmed feasibility and safety of the approach. 

The study is designed to integrate data collection to allow assessment of patient selection, and healthcare related costs. In addition, the perspective of parents and patients will be assessed on presentation, upon 28 days, and six months post randomization to assess quality of life, cognitive and functional outcome, and to inform on patient-relevant value of care delivered. 

The study is unique in combining the expertise of the leading paediatric hospitals in Australia involving the Emergency Department and Paediatric Intensive Care Unit as a continuum of care to address one of the leading killer diseases in children. The study is supported by a very experienced paediatric acute care research network and is strengthened by important patient-centred and economic endpoints such as mortality, utilisation of intensive care resources, and long term impact including extensive assessment of consumer perspective.  

PROTOCOL SYNOPSIS 

Objectives: To investigate in a randomized controlled trial in children presenting with septic shock early intravenous administration of Vitamin C (100 mg/kg 6 h), Thiamine (4 mg/kg 12 h) and Hydrocortisone (1 mg/kg 6 h) and the impact on survival free of intensive care.  

Design: Randomized controlled trial  

Outcomes 

Primary outcome: PICU free survival (censored at 28 days) 

Secondary outcomes:  

  • Survival free of organ support 

  • Survival free of cardiovascular support 

  • Survival free of ventilation 

  • Mortality 

  • Hospital length of stay 

  • Direct hospitalization-related costs 

  • Functional outcome and Quality of Life at 28d and at 6 months post discharge 

Participants: 300 in total 

Population: Children greater than 7 days and less than 18 years where septic shock persists despite initial resuscitation and requiring admission to PICU with ongoing inotrope requirement of greater become eligible for the Intervention. 

Intervention: 

Intervention 1: Early intravenous resuscitation with Hydrocortisone/Vitamin C/Thiamine 

Intervention 2: Intravenous Hydrocortisone only 

Standard Arm 3: No early treatment with Hydrocortisone/Vitamin C/Thiamine 

Study Duration: 36 months 

INVESTIGATORS: 

Study Management Committee: 

A/Prof Luregn Schlapbach, Queensland Children’s Hospital, and Paediatric Critical Care Research Group, The University of Queensland, Brisbane, QLD 

Dr Sainath Raman, Queensland Children’s Hospital, and Paediatric Critical Care Research Group, The University of Queensland, Brisbane, QLD 

Prof Rinaldo Bellomo, Director of Intensive Care Research at the Austin Hospital; Professor of Intensive Care Medicine, University of Melbourne; Honorary Professor, Monash University, The George Institute of Global Health, University of Sydney 

A/Prof Kristen Gibbons, Statistical Expert, The University of Queensland, Brisbane 

Dr Simon Erickson, Perth Children`s Hospital 

Dr Ben Gelbart, Royal Children`s Hospital Melbourne 

Dr Shane George, Gold Coast University Hospital 

  

Site investigators and site contacts: 

Queensland Children`s Hospital: 

Dr Sainath Raman 

A/Prof Luregn Schlapbach 

Ms Amanda Harley 

Ms Roberta Ridolfi 

Ms Natalie Sharp 

A/Prof Debbie Long (Follow-Up lead) 

Ms Michele Cree (Pharmacy lead) 

 

Gold Coast University Hospital: 

A/Prof Shane George 

 

Sunshine Coast University Hospital: 

Dr Paula Lister 

Dr Jessica Mills 

 

Royal Children`s Hospital Melbourne: 

Dr Ben Gelbart 

Carmel Delzoppo 

Warwick Butt 

 

Perth Children`s Hospital, Perth: 

Dr Simon Erickson  

 

Women's and Children's Hospital, Adelaide 

Dr Subodh Ganu 

 

Sydney Children`s Hospital, Sydney: 

Dr Puneet Singh 

 

The Children’s Hospital at Westmead, Sydney  

Dr Marino Festa 

Dr Chong Tien Goh 

 

Starship Children`s Hospital, Auckland, NZ. 

Dr David Buckely  

Dr John Beca  

 

University Children`s Hospital Zurich, Zurich, Switzerland. 

Prof. Luregn Schlapbach 

Previous
Previous

PICU Follow-up Practices Survey

Next
Next

NECTAR